Mitomycin Accord

Mitomycin, the active ingredient in Mitomycin Accord, is an antineoplastic antibiotic presented as an injectable for intravenous use. It is employed in cancer chemotherapy to treat various solid tumours in adult patients.

GNH USA supplies Mitomycin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Mitomycin is used in oncology to target rapidly dividing cancer cells across several tumour types.

- Bladder cancer (intravesical): reduces tumour recurrence after transurethral resection. - Gastric cancer: incorporated into combination regimens to improve response rates. - Pancreatic cancer: part of multi‑drug protocols to achieve tumour control.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Mucositis: inflammation of the oral and gastrointestinal mucosa. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Renal toxicity: elevated creatinine levels.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe neutropenia: heightened infection risk. - Hemolytic‑uremic syndrome: acute kidney injury with hemolysis. - Cardiotoxicity: reduced cardiac function. - Anaphylactic reactions: severe hypersensitivity. - Secondary malignancies: rare development of new cancers.

Mitomycin requires careful monitoring and specific safety measures before, during, and after administration.

- Renal function: assess creatinine clearance prior to dosing. - Hepatic function: evaluate liver enzymes to adjust therapy. - Hematologic status: perform baseline complete blood count. - Pulmonary assessment: consider baseline lung function tests. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Antimetabolites (e.g., methotrexate): increased myelosuppression. - High‑dose radiation therapy: heightened tissue damage. - Nephrotoxic agents (e.g., cisplatin): amplified renal toxicity.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): possible reduced plasma levels. - Anticoagulants (e.g., warfarin): enhanced bleeding risk. - Immunosuppressants (e.g., cyclosporine): additive infection risk.